|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,398,000 |
Market
Cap: |
310.06(M) |
Last
Volume: |
832,955 |
Avg
Vol: |
701,733 |
52
Week Range: |
$3.38 - $6.66 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 803 |
Guru Rank Value : 1 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
121,098 |
121,098 |
148,134 |
388,157 |
Total Sell Value |
$513,345 |
$513,345 |
$684,141 |
$2,735,436 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
10 |
10 |
14 |
33 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Tang Capital Partners Lp |
10% Owner |
|
2010-01-05 |
4 |
S |
$11.48 |
$522,263 |
I/I |
(45,500) |
2,920,352 |
|
- |
|
Tang Capital Partners Lp |
10% Owner |
|
2010-01-04 |
4 |
S |
$11.65 |
$1,165,320 |
I/I |
(100,000) |
2,965,852 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2009-12-15 |
5 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
405,000 |
|
- |
|
Ramsay David Russ |
Director |
|
2009-12-15 |
4 |
S |
$11.03 |
$1,091,132 |
I/I |
(98,924) |
200,000 |
|
- |
|
Karabelas Argeris N |
Director |
|
2009-12-15 |
4 |
S |
$11.03 |
$1,091,132 |
I/I |
(98,924) |
200,000 |
|
- |
|
Clark William D |
Sr. VP, Chief Business Officer |
|
2009-12-14 |
4 |
S |
$11.05 |
$2,406,431 |
D/D |
(217,749) |
152,801 |
|
- |
|
Clark William D |
Sr. VP, Chief Business Officer |
|
2009-12-14 |
4 |
OE |
$0.33 |
$97,827 |
D/D |
295,550 |
370,550 |
|
- |
|
Ramsay David Russ |
Director |
|
2009-12-14 |
4 |
S |
$11.14 |
$1,448,200 |
I/I |
(130,000) |
298,924 |
|
- |
|
Karabelas Argeris N |
Director |
|
2009-12-14 |
4 |
S |
$11.14 |
$1,448,200 |
I/I |
(130,000) |
298,924 |
|
- |
|
Ramsay David Russ |
Director |
|
2009-12-09 |
4 |
S |
$11.57 |
$1,240,304 |
I/I |
(107,200) |
428,924 |
|
- |
|
Karabelas Argeris N |
Director |
|
2009-12-09 |
4 |
S |
$11.57 |
$1,240,304 |
I/I |
(107,200) |
428,924 |
|
- |
|
Ramsay David Russ |
Director |
|
2009-12-08 |
4 |
S |
$11.30 |
$298,049 |
I/I |
(26,376) |
536,124 |
|
- |
|
Karabelas Argeris N |
Director |
|
2009-12-08 |
4 |
S |
$11.30 |
$298,049 |
I/I |
(26,376) |
536,124 |
|
- |
|
Karabelas Argeris N |
Director |
|
2009-12-07 |
4 |
S |
$11.57 |
$1,157,000 |
I/I |
(100,000) |
562,500 |
|
- |
|
Ramsay David Russ |
Director |
|
2009-12-07 |
4 |
S |
$11.57 |
$1,157,000 |
I/I |
(100,000) |
562,500 |
|
- |
|
Karabelas Argeris N |
Director |
|
2009-12-04 |
4 |
S |
$11.70 |
$1,170,000 |
I/I |
(100,000) |
662,500 |
|
- |
|
Ramsay David Russ |
Director |
|
2009-12-04 |
4 |
S |
$11.70 |
$1,170,000 |
I/I |
(100,000) |
662,500 |
|
- |
|
Feeney John Joseph |
Acting Chief Medical Officer |
|
2009-11-06 |
4 |
S |
$10.33 |
$146,809 |
D/D |
(14,217) |
0 |
|
- |
|
Feeney John Joseph |
Acting Chief Medical Officer |
|
2009-11-06 |
4 |
OE |
$1.02 |
$91,098 |
D/D |
14,217 |
14,217 |
|
- |
|
Tang Capital Partners Lp |
10% Owner |
|
2009-10-15 |
4 |
S |
$11.80 |
$683,782 |
I/I |
(57,928) |
3,065,852 |
|
- |
|
Tang Capital Partners Lp |
10% Owner |
|
2009-10-13 |
4 |
S |
$12.76 |
$6,918,844 |
I/I |
(542,072) |
3,123,780 |
|
- |
|
Karabelas Argeris N |
Director |
|
2009-10-13 |
4 |
S |
$12.65 |
$3,004,375 |
I/I |
(237,500) |
762,500 |
|
- |
|
Ramsay David Russ |
Director |
|
2009-10-13 |
4 |
S |
$12.65 |
$3,004,375 |
I/I |
(237,500) |
762,500 |
|
- |
|
Feeney John Joseph |
Acting Chief Medical Officer |
|
2009-05-18 |
4 |
S |
$12.00 |
$78,744 |
D/D |
(6,562) |
0 |
|
- |
|
Feeney John Joseph |
Acting Chief Medical Officer |
|
2009-05-13 |
4 |
S |
$12.00 |
$36,000 |
D/D |
(3,000) |
9,562 |
|
- |
|
549 Records found
|
|
Page 14 of 22 |
|
|